351 related articles for article (PubMed ID: 20093894)
1. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Harper M; Thom E; Klebanoff MA; Thorp J; Sorokin Y; Varner MW; Wapner RJ; Caritis SN; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM; Anderson GD;
Obstet Gynecol; 2010 Feb; 115(2 Pt 1):234-242. PubMed ID: 20093894
[TBL] [Abstract][Full Text] [Related]
2. The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
Kuper SG; Abramovici AR; Jauk VC; Harper LM; Biggio JR; Tita AT
Am J Obstet Gynecol; 2017 Oct; 217(4):476.e1-476.e6. PubMed ID: 28549983
[TBL] [Abstract][Full Text] [Related]
3. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
4. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
5. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
Saccone G; Khalifeh A; Elimian A; Bahrami E; Chaman-Ara K; Bahrami MA; Berghella V
Ultrasound Obstet Gynecol; 2017 Mar; 49(3):315-321. PubMed ID: 27546354
[TBL] [Abstract][Full Text] [Related]
6. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
[TBL] [Abstract][Full Text] [Related]
7. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
8. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
9. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
[TBL] [Abstract][Full Text] [Related]
10. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
[TBL] [Abstract][Full Text] [Related]
11. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
12. Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Saha PT; Mbewe FM; Phiri WM; Peterson M; Muyangwa D; Sindano N; Mwape H; Smithmyer ME; Kasaro MP; Rouse DJ; Goldenberg RL; Chomba E; Stringer JSA
Lancet HIV; 2021 Oct; 8(10):e605-e613. PubMed ID: 34509197
[TBL] [Abstract][Full Text] [Related]
13. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
[TBL] [Abstract][Full Text] [Related]
14. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
[TBL] [Abstract][Full Text] [Related]
15. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
16. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
18. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
Rouse DJ; Caritis SN; Peaceman AM; Sciscione A; Thom EA; Spong CY; Varner M; Malone F; Iams JD; Mercer BM; Thorp J; Sorokin Y; Carpenter M; Lo J; Ramin S; Harper M; Anderson G;
N Engl J Med; 2007 Aug; 357(5):454-61. PubMed ID: 17671253
[TBL] [Abstract][Full Text] [Related]
19. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 fatty acid addition during pregnancy.
Middleton P; Gomersall JC; Gould JF; Shepherd E; Olsen SF; Makrides M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD003402. PubMed ID: 30480773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
